The US Food and Drug Administration (FDA) has granted approval for Zydus Lifesciences’ new drug application for Zituvimet tablets (sitagliptin and metformin hydrochloride) 50 mg/500 mg and 50 mg/1000 mg for type 2 diabetes mellitus in adults.
Zituvimet is intended for use as an adjunct to diet and exercise.
The treatment could enhance glycaemic control in type 2 diabetes mellitus patients.
Zituvimet is a fixed-dose mixture of two active ingredients, sitagliptin and metformin hydrochloride (HCl).
Sitagliptin is an inhibitor of dipeptidyl peptidase-4 (DPP-4) and metformin hydrochloride is a biguanide.
Two dosages, sitagliptin 50 mg and metformin HCl 500 mg tablets, and sitagliptin 50 mg and metformin HCl 1,000 mg tablets, were approved by the regulator.
Zituvimet was also tested for genotoxic impurities and nitrosamines and was found to be compliant with the latest US FDA standards.
Zydus Lifesciences managing director Dr Sharvil Patel stated: “The Zituvimet approval further builds on our previous approval of Zituvio (sitagliptin) and offers increased accessibility and affordability to healthcare systems with regard to prescription drugs for type II diabetes.
“The Zituvimet approval provides an affordable treatment option for healthcare systems to reduce the rate of growth in drug spending, and improves the financial sustainability of the healthcare programmes.”
Zituvimet is not intended for treating type 1 diabetes mellitus patients and those with a history of pancreatitis.
“US FDA approves Zydus’ Zituvimet for type 2 diabetes mellitus ” was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
by: GlobalData
published on GlobalData